William Blair Reaffirms "Outperform" Rating for Dynavax Technologies (NASDAQ:DVAX)

Dynavax Technologies (NASDAQ:DVAX - Get Free Report)'s stock had its "outperform" rating restated by equities research analysts at William Blair in a research report issued to clients and investors on Friday,RTT News reports. William Blair also issued estimates for Dynavax Technologies' Q1 2025 earnings at $0.03 EPS, Q2 2025 earnings at $0.09 EPS, Q3 2025 earnings at $0.12 EPS, Q4 2025 earnings at $0.04 EPS, FY2025 earnings at $0.28 EPS, Q1 2026 earnings at $0.11 EPS, Q2 2026 earnings at $0.18 EPS, Q3 2026 earnings at $0.21 EPS, Q4 2026 earnings at $0.11 EPS and FY2026 earnings at $0.61 EPS.

Other equities research analysts have also issued research reports about the company. StockNews.com lowered Dynavax Technologies from a "buy" rating to a "hold" rating in a research report on Wednesday, February 12th. HC Wainwright restated a "buy" rating and set a $31.00 price target on shares of Dynavax Technologies in a research report on Friday. Finally, The Goldman Sachs Group downgraded shares of Dynavax Technologies from a "neutral" rating to a "sell" rating and decreased their price objective for the stock from $15.00 to $12.00 in a research report on Tuesday, February 11th.

Dynavax Technologies Stock Performance

Shares of Dynavax Technologies stock traded down $0.01 during trading on Friday, hitting $13.41. 1,783,038 shares of the company's stock were exchanged, compared to its average volume of 1,834,979. The stock has a market capitalization of $1.76 billion, a price-to-earnings ratio of 74.50 and a beta of 1.32. The business has a 50-day simple moving average of $12.83 and a 200-day simple moving average of $12.06. Dynavax Technologies has a 52-week low of $9.74 and a 52-week high of $14.05. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, meeting analysts' consensus estimates of $0.05. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. The business had revenue of $72.03 million during the quarter, compared to analyst estimates of $72.70 million. On average, research analysts forecast that Dynavax Technologies will post 0.32 EPS for the current year.

Hedge Funds Weigh In On Dynavax Technologies

A number of large investors have recently added to or reduced their stakes in DVAX. Deep Track Capital LP increased its stake in shares of Dynavax Technologies by 42.0% during the fourth quarter. Deep Track Capital LP now owns 17,791,486 shares of the biopharmaceutical company's stock worth $227,197,000 after purchasing an additional 5,265,000 shares in the last quarter. Deerfield Management Company L.P. Series C increased its stake in Dynavax Technologies by 23,990.1% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 5,193,823 shares of the biopharmaceutical company's stock worth $66,325,000 after buying an additional 5,172,263 shares in the last quarter. Assenagon Asset Management S.A. purchased a new stake in Dynavax Technologies during the 3rd quarter worth approximately $8,291,000. Norges Bank acquired a new position in shares of Dynavax Technologies during the fourth quarter valued at approximately $7,762,000. Finally, D. E. Shaw & Co. Inc. lifted its position in shares of Dynavax Technologies by 34.0% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,918,340 shares of the biopharmaceutical company's stock valued at $24,497,000 after acquiring an additional 486,981 shares in the last quarter. 96.96% of the stock is currently owned by institutional investors and hedge funds.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.